Cefuroxime, a new parenteral cephalosporin was compared with cephalothin by broth microdilution susceptibility testing against 5,887 routine clinical bacterial isolates in four large clinical laboratories. The minimal inhibitory concentrations (MICs) of cefuroxime against the Enterobacteriaceae were consistently lower than those of cephalothin. This was most striking among the Enterobacter species, which were generally susceptible to cefuroxime (MIC < 8 ,g/ml), but resistant to cephalothin. Similar results occurred with Haemophilus species, Acinetobacter anitratus, meningococci, and Aeromonas hydrophilia, but Pseudomonas species and enterococci were resistant to high concentrations of both drugs. Streptococci showed slightly greater susceptibility to cefuroxime than to cephalothin. By contrast, staphylococci were more susceptible to cephalothin.
Cefuroxime, a new parenteral cephalosporin was compared with cephalothin by broth microdilution susceptibility testing against 5,887 routine clinical bacterial isolates in four large clinical laboratories. The minimal inhibitory concentrations (MICs) of cefuroxime against the Enterobacteriaceae were consistently lower than those of cephalothin. This was most striking among the Enterobacter species, which were generally susceptible to cefuroxime (MIC < 8 ,g/ml), but resistant to cephalothin. Similar results occurred with Haemophilus species, Acinetobacter anitratus, meningococci, and Aeromonas hydrophilia, but Pseudomonas species and enterococci were resistant to high concentrations of both drugs. Streptococci showed slightly greater susceptibility to cefuroxime than to cephalothin. By contrast, staphylococci were more susceptible to cephalothin. Bacteroides fragilis was resistant to cefuroxime, but other anaerobes were generally susceptible.
Cefuroxime [(6R,7R)-3-carbamoyloxymethyl-7-(2Z)-2-methoximino(fur-2-yl)-acetamidoceph-3-em-4-carboxylic acid] is a new semisynthetic cephalosporin. This parenteral antibiotic has a broad antimicrobial spectrum offering potential therapeutic advantages over currently available cephalosporins (2, 3, (6) (7) (8) (9) (10) .
This study compares its in vitro antimicrobial activity with that of cephalothin. The study uses a large number of clinical bacterial isolates from four collaborating laboratories in three widely separated geographic areas. Susceptibility testing of S. pneumoniae, several beta-hemolytic streptococci, and Haemophilus species was performed in Mueller-Hinton broth supplemented with 5% peptic digest of horse cells. For anaerobic susceptibility testing, brain heart infusion broth containing 0.1 ,ug of menadione and 0.01 pLg ofhemin per ml and the methods described previously (5) Cefuroxime demonstrated a marked antimicrobial activity against N. meningitidis strains. Seventy-two percent of the tested isolates was inhibited at 0.06 ,ug/ml or less. 
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This study compared the antimicrobial activity of a new parenteral cephalosporin, cefuroxime, with that of cephalothin on a large number of clinical bacterial isolates from three geographic areas. Several reports have noted that cefuroxime has a more active gram-negative spectrum, particularly among the Enterobacteriaceae and Neisseria species (2, (6) (7) (8) 10) .
Seven commonly encountered bacterial species were subjected to statistical analysis. The Kalmogorov-Smirnov two-sample test of significance was used to compare the susceptibility of these organisms to cefuroxime and cephalothin. Bacteroides and Fusobacterium species (5) 80 100
Gram-positive nonsporulating bacillic (4) 75 100 Eubacterium species (2) 100 a Includes Clostridium perfringens (21), C. ramosum (3), C. butyricum (2) , and one isolate each of C. septicum, C. paraputrifwum, C. oroticum, and C. lentoputrescens.
b Includes Peptococcus asaccharolyticus (2) and P. variabilis (2) , and one isolate each ofPeptostreptococcus intermedius, P. anaerobius, Peptococcus magnus, P. morbillorum, and Ruminococcus bromii.
r Includes Propionibacterium acnes (2), Lactobacillus acidophilus (1) and Lactobacillus species (1).
marcescens were significantly (P = <0.001) more susceptible to cefuroxime at all tested concentrations (c 32 gg/ml). Moreover, equally significant cefuroxime antimicrobial activity was demonstrated against E. coli, K. pneumoniae, and P. mirabilis up to concentrations of 16, 4, and 8 ,ug/ml, respectively. Cephalothin was more active than cefuroxime (P = <0.001) against the S. aureus isolates at concentrations of_ 1 ,g/ml. In addition, no statistically significant susceptibility differences were encountered among collaborating institutions. Like other cephalosporin antimicrobial agents, cefuroxime appears to have a limited spectrum against P. aeruginosa, Pseudomonas speci-es, Enterococci, and B. fragilis (1, 11 (9) .
